{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T16:12:13Z","timestamp":1779034333593,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.toxicon.2021.07.005","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T05:01:06Z","timestamp":1626325266000},"page":"96-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Correction of overactive bladder with botulinum toxin type A (BTX-A)"],"prefix":"10.1016","volume":"200","author":[{"given":"Andrey","family":"Grishin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-4143","authenticated-orcid":false,"given":"Anastasiya","family":"Spaska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyailya","family":"Kayumova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2021.07.005_bib1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.euf.2019.06.006","article-title":"Urinary biomarkers in overactive bladder: revisiting the evidence in 2019","volume":"5","author":"Antunes-Lopes","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.toxicon.2021.07.005_bib2","first-page":"98","article-title":"The efficacy of therapy in patients with neurogenic and idiopathic detrusor hyperactivity depending on the dose of botulinum toxin type A","volume":"3","author":"Arhireev","year":"2017","journal-title":"Eksperimentalnaya i Klinicheskaya Urol."},{"key":"10.1016\/j.toxicon.2021.07.005_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross\u2010sectional, population\u2010based study","volume":"11","author":"Chuang","year":"2019","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"10.1016\/j.toxicon.2021.07.005_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.urology.2019.04.018","article-title":"Outcomes for intravesical abobotulinumtoxin A (Dysport) treatment in the active management of overactive bladder symptoms\u2014a prospective study","volume":"130","author":"Craciun","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.toxicon.2021.07.005_bib5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/nau.23513","article-title":"The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States","volume":"37","author":"Durden","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.toxicon.2021.07.005_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-0036-1594284","article-title":"Botulinum toxin injections in musculoskeletal disorders","volume":"20","author":"Godoy","year":"2016","journal-title":"Semin. Muscoskel. Radiol."},{"key":"10.1016\/j.toxicon.2021.07.005_bib7","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3389\/fphar.2019.01618","article-title":"Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder","volume":"10","author":"Gong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.toxicon.2021.07.005_bib8","first-page":"675","article-title":"Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury","volume":"58","author":"Hebert","year":"2020","journal-title":"S.C."},{"key":"10.1016\/j.toxicon.2021.07.005_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/toxins12040214","article-title":"A proposal for botulinum toxin type A injection into the temporal region in chronic migraine headache","volume":"12","author":"Kim","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2021.07.005_bib10","first-page":"10","article-title":"Application of botulinum toxin type A in correction symptoms of impaired urination in children and adults","volume":"44","author":"Kogan","year":"2011","journal-title":"Effektivnaya Farmakoterapiya"},{"key":"10.1016\/j.toxicon.2021.07.005_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.toxicon.2021.07.005_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/toxins12020129","article-title":"Mechanism of action of botulinum toxin A in treatment of functional urological disorders","volume":"12","author":"Lin","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2021.07.005_bib13","first-page":"21","article-title":"Development of a liposomal dosage form based on hydrophobic derivative of indolocarbazole","volume":"9","author":"Lugen","year":"2020","journal-title":"Drug Dev. & Res."},{"key":"10.1016\/j.toxicon.2021.07.005_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/toxins11080459","article-title":"Mechanisms of botulinum toxin type A action on pain","volume":"11","author":"Matak","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2021.07.005_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.urology.2018.12.021","article-title":"Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population","volume":"126","author":"Mckellar","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.toxicon.2021.07.005_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14397595.2019.1589913","article-title":"Prevalence and clinical characteristics of overactive bladder in systemic sclerosis","volume":"30","author":"Motegi","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.toxicon.2021.07.005_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/nau.23849","volume":"38","author":"Myers","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.toxicon.2021.07.005_bib18","series-title":"Seminars in Neurology","article-title":"Neurogenic bladder: epidemiology, diagnosis, and management","author":"Panicker","year":"2020"},{"key":"10.1016\/j.toxicon.2021.07.005_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.01280-18","article-title":"Natural compounds and their analogues as potent antidotes against the most poisonous bacterial toxin","volume":"84","author":"Patel","year":"2018","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.toxicon.2021.07.005_bib20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxicon.2021.07.005_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11884-016-0344-9","article-title":"The burden of overactive bladder on US public health","volume":"11","author":"Reynolds","year":"2016","journal-title":"Curr. Bladder Dysfunct. Rep."},{"key":"10.1016\/j.toxicon.2021.07.005_bib22","first-page":"415","article-title":"The prevalence of detrusor underactivity and its symptoms co-relation with urodynamic study findings in patients with lower urinary tract symptoms","volume":"12","author":"Sawaqed","year":"2020","journal-title":"Res. Rep. Urol."},{"issue":"4","key":"10.1016\/j.toxicon.2021.07.005_bib23","first-page":"180","article-title":"N-nitrosamine impurities in medicines: toxicity, formation pathways, methods of determination, and limits (review)","volume":"9","author":"Shchetinin","year":"2020","journal-title":"Drug Dev. Reg."},{"key":"10.1016\/j.toxicon.2021.07.005_bib24","first-page":"117","article-title":"Botulinum toxin in low urinary tract disorders-over 30 years of practice","volume":"20","author":"Spinu","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.toxicon.2021.07.005_bib25","first-page":"67","article-title":"Methods and prospects for determination of mycotoxins in medicinal herbal raw materials (review)","volume":"9","author":"Trineeva","year":"2020","journal-title":"Drug Dev. Reg."},{"key":"10.1016\/j.toxicon.2021.07.005_bib26","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1002\/nau.24016","article-title":"Are psychological comorbidities important in the aetiology of lower urinary tract dysfunction\u2014ici\u2010RS 2018?","volume":"38","author":"von Gontard","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.toxicon.2021.07.005_bib27","first-page":"853","article-title":"The whole truth about botulinum toxin-a review","volume":"36","author":"Witmanowski","year":"2019","journal-title":"Advances in Dermatology and Allergol. Postepy Dermatologii i Alergologii"},{"key":"10.1016\/j.toxicon.2021.07.005_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/toxins12020098","article-title":"Effect of botulinum toxin A on bladder pain-molecular evidence and animal studies","volume":"12","author":"Yeh","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2021.07.005_bib29","first-page":"406","article-title":"Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics","volume":"22","author":"Yehoshua","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.toxicon.2021.07.005_bib30","first-page":"26","article-title":"Phase equilibrium of biologically active systems 4,6-dinitro-5,7- dichlorobenzofuroxane and 5-nitro-4,6-dichlorobenzofuroxane","volume":"9","author":"Yusupova","year":"2020","journal-title":"Drug Dev. & Res."},{"key":"10.1016\/j.toxicon.2021.07.005_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.toxicon.2018.01.019","article-title":"Evidence on botulinum toxin in selected disorders","volume":"147","author":"Zakin","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2021.07.005_bib32","article-title":"Effects and safety of herbal medicines on patients with overactive bladder: a protocol for a systematic view and meta-analysis","volume":"98","author":"Zhou","year":"2019","journal-title":"Medicine"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010121002014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010121002014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:19:17Z","timestamp":1758575957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010121002014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":32,"alternative-id":["S0041010121002014"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2021.07.005","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correction of overactive bladder with botulinum toxin type A (BTX-A)","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2021.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}